Single-Batch Production of Recombinant Human Polyclonal Antibodies
Open Access
- 20 March 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Biotechnology
- Vol. 45 (3), 257-266
- https://doi.org/10.1007/s12033-010-9270-9
Abstract
We have previously described the development and implementation of a strategy for production of recombinant polyclonal antibodies (rpAb) in single batches employing CHO cells generated by site-specific integration, the SympressTM I technology. The SympressTM I technology is implemented at industrial scale, supporting a phase II clinical development program. Production of recombinant proteins by site-specific integration, which is based on incorporation of a single copy of the gene of interest, makes the SympressTM I technology best suited to support niche indications. To improve titers while maintaining a cost-efficient, highly reproducible single-batch manufacturing mode, we have evaluated a number of different approaches. The most successful results were obtained using random integration in a new producer cell termed ECHO, a CHO DG44 cell derivative engineered for improved productivity at Symphogen. This new expression process is termed the SympressTM II technology. Here we describe proof-of-principle data demonstrating the feasibility of the SympressTM II technology for single-batch rpAb manufacturing using two model systems each composed of six target-specific antibodies. The compositional stability and the batch-to-batch reproducibility of rpAb produced by the ECHO cells were at least as good as observed previously using site-specific integration technology. Furthermore, the new process had a significant titer increase.Keywords
This publication has 16 references indexed in Scilit:
- Manufacture of recombinant polyclonal antibodiesBiotechnology Letters, 2007
- Isolation of Human Antibody Repertoires with Preservation of the Natural Heavy and Light Chain PairingJournal of Molecular Biology, 2006
- Production of target‐specific recombinant human polyclonal antibodies in mammalian cellsBiotechnology & Bioengineering, 2006
- Recombinant polyclonal antibodies for cancer therapyJournal of Cellular Biochemistry, 2005
- Production of recombinant protein therapeutics in cultivated mammalian cellsNature Biotechnology, 2004
- Passive antibody therapy for infectious diseasesNature Reviews Microbiology, 2004
- High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6Biotechnology Progress, 2003
- Higher Productivity of Growth-Arrested Chinese Hamster Ovary Cells Expressing the Cyclin-Dependent Kinase Inhibitor p27Biotechnology Progress, 1998
- Return to the Past: The Case for Antibody-Based Therapies in Infectious DiseasesClinical Infectious Diseases, 1995
- Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian CellsScience, 1991